Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension

Çi̇men, Tolga; Bi̇lgi̇n, Murat; Akyel, Ahmet; Felekoğlu, Mehmet Ali; Nallbani, Ali; Özdemir, Şeyda; Erden, Gönül; Öztürk, Alpaslan; Doğan, Mehmet; Yeter, Ekrem

doi:10.4070/kcj.2016.46.6.827

Cited by 10 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oktar et al have recently evaluated plasma endocan levels in patients with newly diagnosed HT [ 27 ]. Significantly elevated endocan levels in HT have already been reported in previous studies [ 28 , 29 ]. However, the study by Oktar et al was the first to indicate that microalbuminuria is elevated in patients with newly diagnosed HT and that it positively correlates with endocan concentrations.…”

Section: Endocan In Ckdsupporting

confidence: 77%

The Role of Endocan in Selected Kidney Diseases

Nalewajska

Gurazda

Marchelek-Myśliwiec

et al. 2020

IJMS

View full text Add to dashboard Cite

Endocan, previously referred to as an endothelial-cell-specific molecule-1 (ESM-1) is a member of a proteoglycan family that is secreted by vascular endothelial cells of different organs, mainly lungs and kidneys. It is assumed to participate in endothelial activation and the triggering of inflammatory reactions, especially in microvasculatures. Thanks to its solubility in human fluids, i.e., urine and blood plasma, its stability and its low concentrations in physiological conditions, endocan has been proposed as an easily available, non-invasive biomarker for identifying and predicting the course of many diseases. Recently, endocan has been studied in relation to kidney diseases. In general, endocan levels have been linked to worse clinical outcomes of renal dysfunction; however, results are conflicting and require further evaluation. In this review, authors summarize available knowledge regarding the role of endocan in pathogenesis and progression of selected kidney diseases.

show abstract

Section: Endocan In Ckdsupporting

confidence: 77%

The Role of Endocan in Selected Kidney Diseases

Nalewajska

Gurazda

Marchelek-Myśliwiec

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Finally, 15 articles involving a total of 3097 subjects met the inclusion criteria for our meta-analysis. [9–23] Of these, there were 8 papers about coronary artery disease (CAD), [10,12–18] 6 about hypertension, [9,11,15,16,22,23] and 3 about coronary flow slow [19–21] (Table 1). A flowchart of the study selection progress with specific reasons for exclusion is displayed in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease

Zhao¹,

Yao²,

Zhao

et al. 2018

Medicine

View full text Add to dashboard Cite

Objective:Endothelial dysfunction was widely regarded as the initial lesion in the multifactorial pathogenesis of cardiovascular disease (CVD). Serum endocan, a novel endothelial dysfunction biochemical marker, is involved in the development of CVD. Here, we fulfilled a meta-analysis to evaluate the association between CVD and serum endocan levels.Method:The relevant published literature was searched through large literature databases, including PubMed, Embase, Cochrane Library, SinoMed, and Web of Science, up to June 1, 2018. The data were extracted from the studies. Stata software was used to perform a meta-analysis.Result:Fifteen original studies with a total of 1839 patients and 1258 controls fulfilled the inclusion criteria and were included in the study dataset. Meta-analysis showed that the levels of serum endocan in patients with hypertension, coronary artery disease, and coronary slow flow were higher than those in the control group. The pooled standardized mean differences and 95% confidence intervals of endocan concentrations in those 3 groups were 0.53 [0.19–0.86], P < .01; 0.99 [0.51–1.39], P < .01; and 0.62 [0.45–0.78], P < .01, respectively. Further analysis showed that the level of serum endocan in hypertension patients with coronary artery disease was higher than that in patients with hypertension (0.61 [0.30–0.92], P < .01). Sensitivity analysis and subgroup analysis were use to confirm the above results.Conclusions:In this meta-analysis, we further confirmed that serum endocan level was significantly increased in the CVD population. The high serum endocan level may be one of the risk factors for CVD.

show abstract

“…Other studies have suggested that higher BP in hypertensive patients during the night might lead to greater endothelial damage. Furthermore, greater endothelial damage would lead to higher levels of nocturnal BP 4,49. Isolated nighttime hypertension might predict cardiovascular events 52.…”

Section: Discussionmentioning

confidence: 99%

“…Hypertension, a common chronic condition that affects up to 40% of human adults,1–3 is a major risk factor for stroke, heart attack, and other vascular as well as renal and metabolic diseases 2,4–7. Hypertension, which is associated with target organ damage (TOD),8 is a serious cause of cardiovascular and cerebrovascular diseases 9.…”

Section: Introductionmentioning

confidence: 99%

<p>The potential role of testosterone in hypertension and target organ damage in hypertensive postmenopausal women</p>

Li¹,

Ma²,

Wang³

et al. 2019

CIA

View full text Add to dashboard Cite

Objective: The aim of this study was to confirm the potential role of testosterone in hypertension and target organ damage (TOD) in hypertensive postmenopausal women. Methods: A matched group study was conducted. One hundred sixty-one hypertensive postmenopausal women between 45 and 65 years of age were enrolled as group 1. Another 161 age-matched hypertensive men were enrolled as group 2. Ambulatory blood pressure monitoring, echocardiographic imaging, vascular function, sex hormones and clinical characteristics were evaluated. Quantitative data were analyzed using independent Student’s t -test and multiple regression analysis. Results: The mean and load level of blood pressure were lower in women than in men ( P <0.05), except for the mean level and load of the nocturnal systolic blood pressure (SBP) (123.77±15.72 mmHg vs 126.35±15.64 mmHg, and 50.43±30.31% vs 55.35±28.51%, P >0.05). However, the carotid-femoral pulse wave velocity (cf-PWV) in women was higher than that in men (9.68±2.23 m/s vs 8.03±2.82 m/s, P <0.05). The ratio of the early diastolic mitral peak flow velocity to early diastolic mitral annular velocity (E/Em) was obviously impaired (13.06±3.53 vs 12.05±3.68, P <0.05) in women. Furthermore, in women, a positive correlation was found between testosterone and cf-PWV (γ=0.157, P =0.046), and Cf-PWV was positively related to the mean level of nighttime SBP (γ=0.210, P =0.008). Moreover, nocturnal SBP was a risk factor for E/Em (γ=0.156, P =0.048, P <0.05). Conclusion: Testosterone may play a role in the correlation between hypertension and TOD in hypertensive postmenopausal women. Clinical Trial number: This research study was registered under the ClinicalTrials.gov PRS Website (NCT03451747).

show abstract

Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension

Cited by 10 publications

References 29 publications

The Role of Endocan in Selected Kidney Diseases

The Role of Endocan in Selected Kidney Diseases

The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease

<p>The potential role of testosterone in hypertension and target organ damage in hypertensive postmenopausal women</p>

Contact Info

Product

Resources

About